Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: The candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study

Journal of Hypertension

Volumn 20, Issue 11, 2002, Pages 2293-2300

  Cuspidi, Cesare ^a   Muiesan, M Lorenza ^b   Valagussa, Laura ^a   Salvetti, Massimo ^b   Di Biagio, Carlo ^c   Agabiti Rosei, Enrico ^b   Magnani, Bruno ^c   Zanchetti, Alberto ^a   Bartoli, E ^d   Bux, F ^d   Calcaterra, V ^d   Pancaldi, S ^d   Capucci, A ^d   Devenuto, G ^d   De Cesaris, R ^d   Di Biase, G ^d   Di Pasquale, G ^d   Guglielmi, M ^d   Mezzetti, A ^d   Pinelli, G ^d   Pinna, G ^d   Portaluppi, F ^d   Russo, I ^d   Saba, G ^d   Scarpelli, T ^d   Uslenghi, E ^d   Keck, M ^d   Beyer, T ^d   Tepel, K H ^d   Schobel, H ^d   Stolzel, U ^d   Metscher, B ^d   Gehlhar, S ^d   Loos, H ^d   Busch, K ^d   Clasen, G ^d   Muller, T R ^d   Colberg, K ^d   Ulbrich, C ^d   Langguth, D ^d   Mitrovich, V ^d   Regitz Zagrosek, V ^d   Rittich, M ^d   Weber, J L ^d   more..

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d NONE

Author keywords

Drugs; Echocardiography; Hypertension; Hypertrophy

Indexed keywords

CANDESARTAN HEXETIL; ENALAPRIL; HYDROCHLOROTHIAZIDE; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; CANDESARTAN; TETRAZOLE DERIVATIVE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; HEART INDEX; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; BLOOD PRESSURE; ECHOCARDIOGRAPHY; ECHOGRAPHY; HEART RATE; HYPERTENSION; MIDDLE AGED;

ADULT; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; ECHOCARDIOGRAPHY; ENALAPRIL; FEMALE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME;

EID: 0036855573     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200211000-00030     Document Type: Article

References (31)

1. Liebson PR, Grandits GA, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOHMS). Circulation 1995; 91:698-706.
2. Schmieder RE, Schlaich MF, Klingbeil AU, Martus P. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1998). Nephrol Dial Transplant 1998; 13:564-569.
3. Trimarco B, De Luca N, Ricciardelli B, Rosiello G, Volpe M, Condorelli G, et al. Cardiac function in systemic hypertension before and after reversal of left ventricular hypertrophy. Am J Cardiol 1988; 62:745-750.
4. Perlini S, Muiesan ML, Cuspidi C, Sampieri L, Trimarco B, Aurigemma GP, et al. Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry. Circulation 2001; 103:678-683.
5. Magrini F, Reggiani P, Roberts N, Meazza R, Ciulla M, Zanchetti A. Effects of angiotensin blockade on coronary circulation and coronary reserve. Am J Med 1988; 84:55-60.
6. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
7. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
8. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, et al. Prognostic significance of serial change in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
9. Dahlof B, Pennert K, Hansson L Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment study. Am J Hypertens 1992; 5:95-110.
10. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J Hum Hypertens 1992; 6:85-90.
11. Schmieder RE, Martus P, Klingbeil AU. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275:1507-1513.
12. Pitt B. Regression of left ventricular hypertrophy in patients with hypertension. Blockade of the renin-angiotensin-aldosterone system. Circulation 1998; 98:1987-1989.
13. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-1865.
14. Jacobi J, Delles C, Schobel HP, Schlaich MP, Delles C, Schobel HP, Schmieder RE. Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999; 12:418-422.
15. Dahlof B, Devereux RB, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:995-1003.
16. Dahlof B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens 2001; 14:174-182.
17. Villatico-Campbell S, Rizzo V, Di Maio F, Petritto F, Carmenini G, Marigliano V. Antihypertensive therapy with losartan and fosinopril: Efficacy in left ventricular hypertrophy regression [Abstract]. Am J Hypertens 1998; 11:125A.
18. Verdecchia P, Schillaci P, Reboldi GP, Sacchi N, Bruni B, Benemio G, Porcellati C. Long-term effects of losartan and enalapril, alone or with a diuretic, on ambulatory blood pressure and cardiac performance in hypertension: A case-control study. Blood Press Monit 2000; 5:187-193.
19. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55:613-618.
20. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Sachas I, Echocardiographic assessment of left ventricular hypertrophy comparison to necropsy findings. Am J Cardiol 1986; 57:450-458.
21. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PC, et al. Patterns of left ventricular hypertrophy and geometric remodelling in essential hypertension. J Am Coll Cardiol 1992; 19:1550-1558.
22. Spirito P, Maron BJ. Doppler echocardiography for assessing left ventricular diastolic function. Ann Intern Med 1988; 109:122-126.
23. Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98:2037-2042.
24. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L, et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19:1167-1176.
25. Dahlof B, Hansson L. The influence of antihypertensive therapy on the structural vascular amplifying mechanism in essential hypertension. Different effects of enalapril and hydrochlorothiazide. J Hypertens 1992; 10:1513-1524.
26. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement [PRESERVE) trial. Circulation 2001; 104:1248-1254.
27. Agabiti-Rosei E, Ambrosioni E, Dal Palù C, Muiesan ML, Zanchetti A on behalf of the RACE study group. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study. J Hypertens 1995; 13:1325-1334.
28. Terpstra WL, May JF, Smit AJ, de Graeff PA, Havinga TK, van der Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: The ELVERA trial. J Hypertens 2001; 19:303-309.
29. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg; the LIVE study. J Hypertens 2000; 18:1465-1475.
30. Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95:1464-1470.
31. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy. Am J Hypertens 1998; 11:387-396.